Cell Death and Disease<\/a><\/em>.<\/p>\nEn el marc d’aquest estudi col\u00b7laboratiu, a escala internacional, s’ha identificat que els nivells de miR-518d-5p<\/strong> (mol\u00e8cula reguladora de l’expressi\u00f3 g\u00e8nica) en s\u00e8rum estan augmentats en pacients amb c\u00e0ncer hep\u00e0tic. La identificaci\u00f3 d’aquesta mol\u00e8cula en sang s’associa a una major resist\u00e8ncia al tractament amb el medicament Sorafenib<\/strong> i una menor superviv\u00e8ncia global dels pacients amb carcinoma hepatocel\u00b7lular. Aix\u00ed mateix, la inhibici\u00f3, per aproximacions gen\u00f2miques, d’aquesta miR-518d-5p es pot relacionar amb un augment de la sensibilitat de les c\u00e8l\u00b7lules d’hepatoma hum\u00e0 al Sorafenib, aix\u00ed com en models experimentals precl\u00ednics de c\u00e0ncer hep\u00e0tic.<\/p>\n“Els micro-RNAs (miRNAs) s\u00f3n mol\u00e8cules reguladores de l’expressi\u00f3 g\u00e8nica. Un sol miRNA \u00e9s capa\u00e7 de modular l’expressi\u00f3 de m\u00faltiples gens que estan implicats en processos associats al desenvolupament d’una patologia multifactorial. Gr\u00e0cies al seu ampli espectre d’acci\u00f3, aquestes mol\u00e8cules podrien usar-se com a noves eines terap\u00e8utiques per al tractament de malalties complexes”, explica la Dra. Malu Mart\u00ednez Chantar.<\/p>\n
<\/p>\n
Sis\u00e8 c\u00e0ncer m\u00e9s freq\u00fcent a escala mundial<\/h3>\n
El carcinoma hepatocel\u00b7lular<\/strong> \u00e9s el sis\u00e8 c\u00e0ncer m\u00e9s freq\u00fcent a tot el m\u00f3n i la tercera causa de mort relacionada amb el c\u00e0ncer. Malgrat els aven\u00e7os recents en el seu tractament, la superviv\u00e8ncia a llarg termini i el benestar dels pacients continuen sent reptes m\u00e8dics i cient\u00edfics. El Sorafenib \u00e9s un dels f\u00e0rmacs sist\u00e8mics en primera l\u00ednia que est\u00e0 indicat per al tractament del carcinoma hepatocel\u00b7lular. No obstant aix\u00f2, la relaci\u00f3 directa entre el seu \u00fas i la superviv\u00e8ncia dels pacients dep\u00e8n de les caracter\u00edstiques dels malalts. Per tant, \u00e9s essencial estudiar els mecanismes espec\u00edfics de senyalitzaci\u00f3 dels tumors per tal de millorar i predir, en aquest cas, l’activitat antioncog\u00e9nica del Sorafenib. La identificaci\u00f3 de les causes principals de la resist\u00e8ncia al f\u00e0rmac d’alguns pacients permetr\u00e0 abordar la realitzaci\u00f3 de tractaments personalitzats, habilitant l’estratificaci\u00f3 precisa dels pacients inscrits en els assajos cl\u00ednics associats.<\/p>\nEn el treball d’investigaci\u00f3, liderat pel laboratori de Malalties Hep\u00e0tiques de l’CIC bioGUNE que dirigeix la Dra. Malu Mart\u00ednez-Chantar, de l’CIC bioGUNE i CIBER de Malalties Hep\u00e0tiques i Digestives (CIBEREHD), hi han participat el Laboratori de Medicina de Precisi\u00f3 i el laboratori d’Inflamaci\u00f3 i Plasticitat de Macr\u00f2fags (CIC bioGUNE); Hepatologia Experimental i Dianes Farmacol\u00f2giques (HEVEPHARM) de la Universitat de Salamanca; Grup de C\u00e0ncer de Fetge Barcelona-Cl\u00ednic; Unitat de Fetge de l’Institut d’Investigacions Biom\u00e8diques August Pi I Sunyer; Hospital Cl\u00ednic; Universitat de Barcelona; Northern Institute for Cancer Research, The Medical School i Newcastle University (Newcastle upon Tyne); Department of Gastroenterology, Azienda Ospedaliero-Universit\u00e0ria & University of Modena and Reggio Emilia (Modena); Departament de Malalties Hep\u00e0tiques i gastrointestinals de l’Institut de Recerca Biodonostia; Hospital Universitari Donostia, Universitat del Pa\u00eds Basc-Euskal Herriko Unibertsitatea (Donostia-Sant Sebasti\u00e0); Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center (Los Angeles); Grup de TGF-\u03b2 i C\u00e0ncer, Programa Oncobell, Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL) i Universitat de Barcelona; Institut de Salud Carles III; Research Institute for Medicines (iMed.ULisboa), Facultat de Pharmacy, Universidade de Lisboa; IK4-Tekniker; i Ikerbasque, Fundaci\u00f3 Basca per a la Ci\u00e8ncia.<\/p>\n
<\/p>\n
<\/p>\n
L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\nL\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"La identificaci\u00f3 de la mol\u00e8cula miR-518d-5p en sang s’associa a una major resist\u00e8ncia al tractament amb Sorafenib i una menor superviv\u00e8ncia global en els pacients amb carcinoma hepatocel\u00b7lular<\/p>\n","protected":false},"author":8,"featured_media":17970,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,360],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-11 08:46:52","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17969"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=17969"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/17970"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=17969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=17969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=17969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}